# Cizzle Biotechnology to issue shares following £400,000 CLN conversion

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-to-issue-shares-following-400000-cln-conversion/4121250629
- Published: 2026-05-06T07:41:10+01:00
- Author: Amilia Stone

**Cizzle Biotechnology Holdings plc **(LON:CIZ), the UK based diagnostics developer
of early cancer tests, announces that the Company has received a notice to convert
£400,000 of convertible loan notes (CLNs) held by Frazer Lang (registered in the
name of Ropemaker Nominees Limited), an existing investor in the Company.

On 20 May 2025, the Company secured funding of £150,000 through the issue of CLNs
to Frazer Lang and the funding provided by him was extended though the issue of 
further CLNs of £250,000 on 5 November 2025.  The CLNs are convertible at the election
of the Note Holder into new ordinary shares of 0.01p in the Company at a price of
1.4 pence per Ordinary Share.  Following receipt of the conversion notice the Company
will therefore issue 28,571,429 new Ordinary Shares to the Note Holder.

In addition, the Company announced on 2 April 2026 that it has entered into a new
facility to provide the Company with up to £250,000 through the potential issue 
of further unsecured convertible loan notes (“Facility Notes”) to the Note Holder.
The Facility Notes can be drawn down, at the sole election of the Company as to 
£100,000 on 1 May 2026, £100,000 on 1 June and £50,000 on 1 July 2026. The Facility
Notes are convertible at 1.4 pence per Ordinary Share at any time up to 30 October
2026. The Company has now drawn down £100,000 of the Facility Notes and following
completion of the £400,000 CLN conversion, the Note Holder will hold £100,000 of
CLNs.

**Admission and Total Voting Rights**

Application will be made for the 28,571,429 Conversion Shares to be admitted to 
trading on the Main Market of the London Stock Exchange and to listing on the FCA
Official List (“Admission”). It is expected that the issue of the 28,571,429 Conversion
Shares will take place, Admission will become effective and that dealings in the
Conversion Shares on the Main Market of the London Stock Exchange will commence 
on or around 11 May 2026.

On Admission, Cizzle Biotechnology will have 424,963,202 Ordinary Shares in issue,
each with one voting right. There are no shares held in treasury. Therefore, the
Company’s total number of Ordinary Shares and voting rights will be 424,963,202 
and this figure may be used by shareholders from Admission as the denominator for
the calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA’s Disclosure
Guidance and Transparency Rules.

Share on:
